Literature DB >> 25185461

A comparison of long-term outcomes after meticillin-resistant and meticillin-sensitive Staphylococcus aureus bacteraemia: an observational cohort study.

Lai Kin Yaw1, James Owen Robinson2, Kwok Ming Ho3.   

Abstract

BACKGROUND: Findings from previous studies have suggested that outcomes after meticillin-resistant Staphylococcus aureus (MRSA) bacteraemia are worse than after meticillin-sensitive S. aureus (MSSA) bacteraemia. We assessed whether patients who had MRSA bacteraemia had a higher risk of death and recurrent infections than those who had MSSA bacteraemia.
METHODS: For this observational cohort study, we assessed data from the microbiology laboratory database at the Royal Perth Hospital (WA, Australia). Data were for all patients who had an episode of MRSA bacteraemia between July 1, 1997, and June 30, 2007, and, by use of a computer-generated randomisation sequence, a randomly selected subgroup of patients who had an episode of MSSA bacteraemia (patients with one or more set of blood cultures positive for S. aureus). The primary outcomes were survival time and subsequent infection-related hospital readmissions, analysed by Cox proportional hazards regression with adjustment for important prognostic factors.
FINDINGS: Of the 583 patients who had an episode of MRSA or MSSA bacteraemia, we used data for the 582 who had complete data linkage: 185 patients who had MRSA bacteraemia and 397 patients who had MSSA bacteraemia. The crude survival time of patients after MRSA bacteraemia was shorter than it was for patients with MSSA bacteraemia (14 months [IQR 1-86] vs 54 months [3-105]; hazard ratio 1·46, 95% CI 1·18-1·79; p=0·01). The adverse association between MRSA and all-cause mortality (0·98, 0·77-1·30; p=0·87) or infection-related mortality (1·22, 0·89-1·69; p=0·22) were not statistically significant after adjustment for important prognostic factors including age, comorbidities, severity of acute illness, metastatic infections, and long-term care facility resident status. After adjustment for these confounding factors, we saw no difference in infection-related hospital readmissions between patients who had MRSA bacteraemia and those who had MSSA bacteraemia (odds ratio 0·95, 95% CI 0·59-1·53; p=0·83).
INTERPRETATION: Long-term outcomes after MRSA bacteraemia were worse than those after MSSA bacteraemia through its confounding associations with other prognostic factors. Our findings might have implications for management strategies to control MRSA colonisation. FUNDING: The Medical Research Foundation of Royal Perth Hospital.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25185461     DOI: 10.1016/S1473-3099(14)70876-X

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN: 1473-3099            Impact factor:   25.071


  33 in total

1.  [Infections due to multidrug-resistant pathogens : Pathogens, resistance mechanisms and established treatment options].

Authors:  D C Richter; T Brenner; A Brinkmann; B Grabein; M Hochreiter; A Heininger; D Störzinger; J Briegel; M Pletz; M A Weigand; C Lichtenstern
Journal:  Anaesthesist       Date:  2019-10       Impact factor: 1.041

2.  Empirical combination of a β-lactam to vancomycin may not improve outcomes of methicillin-susceptible Staphylococcus aureus bacteremia, compared to vancomycin monotherapy.

Authors:  G E Park; J-H Ko; S Y Cho; Y E Ha; N Y Lee; C-I Kang; D R Chung; J-H Song; K R Peck
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-01-11       Impact factor: 3.267

3.  Reduced Mortality of Staphylococcus aureus Bacteremia in a Retrospective Cohort Study of 2139 Patients: 2007-2015.

Authors:  Eloise D Austin; Sean S Sullivan; Nenad Macesic; Monica Mehta; Benjamin A Miko; Saman Nematollahi; Qiuhu Shi; Franklin D Lowy; Anne-Catrin Uhlemann
Journal:  Clin Infect Dis       Date:  2020-04-10       Impact factor: 9.079

4.  Risk factors for long-term mortality of Staphylococcus aureus bacteremia.

Authors:  D Yahav; S Yassin; H Shaked; E Goldberg; J Bishara; M Paul; L Leibovici
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-02-12       Impact factor: 3.267

5.  Epidemiology of Methicillin-Resistant Staphylococcus aureus Bacteremia in Children.

Authors:  Rana F Hamdy; Alice J Hsu; Chris Stockmann; Jared A Olson; Matthew Bryan; Adam L Hersh; Pranita D Tamma; Jeffrey S Gerber
Journal:  Pediatrics       Date:  2017-05-05       Impact factor: 7.124

6.  Staphylococcus aureus Bacteremia Incidence and Methicillin Resistance in Rural Thailand, 2006-2014.

Authors:  Devan Jaganath; Possawat Jorakate; Sirirat Makprasert; Ornuma Sangwichian; Thantapat Akarachotpong; Somsak Thamthitiwat; Supphachoke Khemla; Triveni DeFries; Henry C Baggett; Toni Whistler; Christopher J Gregory; Julia Rhodes
Journal:  Am J Trop Med Hyg       Date:  2018-05-10       Impact factor: 2.345

7.  De novo methicillin-resistant Staphylococcus aureus vs. methicillin-sensitive Staphylococcus aureus infections of the spine, similar clinical outcome, despite more severe presentation in surgical patients.

Authors:  Basem Ishak; Amir Abdul-Jabbar; Gregory B Moss; Emre Yilmaz; Alexander von Glinski; Sven Frieler; Andreas W Unterberg; Ronan Blecher; Juan Altafulla; Jeffrey Roh; Robert A Hart; Rod J Oskouian; Jens R Chapman
Journal:  Neurosurg Rev       Date:  2020-08-27       Impact factor: 3.042

8.  Cefazolin versus Nafcillin for Methicillin-Sensitive Staphylococcus aureus Bloodstream Infection in a California Tertiary Medical Center.

Authors:  S Pollett; S M Baxi; G W Rutherford; S B Doernberg; P Bacchetti; H F Chambers
Journal:  Antimicrob Agents Chemother       Date:  2016-07-22       Impact factor: 5.191

9.  Staphylococcus aureus bloodstream infections in Latin America: results of a multinational prospective cohort study.

Authors:  Carlos Seas; Coralith Garcia; Mauro J Salles; Jaime Labarca; Carlos Luna; Carlos Alvarez-Moreno; Carlos Mejía-Villatoro; Jeannete Zurita; Manuel Guzmán-Blanco; Eduardo Rodríguez-Noriega; Jinnethe Reyes; Cesar A Arias; Cesar Carcamo; Eduardo Gotuzzo
Journal:  J Antimicrob Chemother       Date:  2018-01-01       Impact factor: 5.790

10.  Readmissions With Multidrug-Resistant Infection in Patients With Prior Multidrug Resistant Infection.

Authors:  Jason P Burnham; Jennie H Kwon; Margaret A Olsen; Hilary M Babcock; Marin H Kollef
Journal:  Infect Control Hosp Epidemiol       Date:  2017-12-17       Impact factor: 3.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.